RxDoctor Payments Data

Marisa Stringer, NP

Nurse Practitioner · Biloxi, MSNPI 1043327034

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,621 of the $68,339 with a category attached, or 63.8%. 22 manufacturers reported payments, led by Sanofi at 47.4% of the total. Among nurse practitioner clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,339in general payments, 2019–2025

Across 390 payments — averaging $175.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$32K
  • Regeneron Healthcare Solutions, Inc.$31K
  • AbbVie$1K
  • Incyte Corporation$1K
  • Galderma Laboratories, L.p.$504
  • Novartis$468
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$3,6755%
  • Speaking & faculty fees$43,62164%
  • Travel & lodging$12,75919%
  • Food & beverage$8,02012%
  • Education$2650%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,339 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$74,018
Medicare patients
265
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab21$183,150
Dupixent PenDupilumab35$128,627
Taltz AutoinjectorIxekizumab13$82,537
RinvoqUpadacitinib12$75,631
Fluorouracil69$5,012
Clobetasol Propionate27$883
Ketoconazole49$744
Clindamycin Phosphate11$502
Imiquimod16$467
Doxycycline Hyclate40$418
ValacyclovirValacyclovir Hcl16$331
Triamcinolone Acetonide43$319
Nystatin20$165
Terbinafine Hcl13$163
Mupirocin13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,333$75,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →